ABSTRACT
Pseudo-Meigs syndrome is a rare syndrome characterized by hydrothorax and ascites associated with pelvic masses, and patients occasionally present with elevated serum cancer antigen-125 (CA125) levels. Hydropic leiomyoma (HLM) is an uncommon subtype of uterine leiomyoma characterized by hydropic degeneration and secondary cystic changes. Rapidly enlarging HLMs accompanied by hydrothorax, ascites, and elevated CA125 levels may be misdiagnosed as malignant tumors. Here, we report a case of HLM in a 45-year-old Chinese woman who presented with ascites and hydrothorax. Preoperative abdominopelvic CT revealed a giant solid mass in the fundus uteri measuring 20 × 15 × 12 cm. Her serum CA125 level was elevated to 247.7 U/ml, while her hydrothorax CA125 level was 304.60 U/ml. The patient was initially diagnosed with uterine malignancy and underwent total abdominal hysterectomy and adhesiolysis. Pathological examination confirmed the presence of a uterine hydropic leiomyoma with cystic changes. After tumor removal, the ascites and hydrothorax subsided quickly, with no evidence of recurrence. The patient's serum CA125 level decreased to 116.90 U/mL on Day 7 and 5.6 U/mL on Day 40 postsurgery. Follow-up data were obtained at 6 months, 1 year, and 2 years after surgery, and no recurrence of ascites or hydrothorax was observed. This case highlights the importance of accurate diagnosis and appropriate management of HLM to achieve successful outcomes.
Subject(s)
CA-125 Antigen , Leiomyoma , Meigs Syndrome , Ovarian Neoplasms , Uterine Neoplasms , Humans , Female , Leiomyoma/diagnosis , Leiomyoma/complications , Middle Aged , CA-125 Antigen/blood , Meigs Syndrome/diagnosis , Uterine Neoplasms/diagnosis , Uterine Neoplasms/complications , Uterine Neoplasms/pathology , Diagnosis, Differential , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/complications , Ovarian Neoplasms/pathology , Ovarian Neoplasms/blood , Ascites/etiology , Ascites/diagnosis , Hydrothorax/etiology , Hydrothorax/diagnosis , Hysterectomy , Membrane ProteinsABSTRACT
Hepatic hydrothorax is a pleural effusion (typically ≥500 mL) that develops in patients with cirrhosis and/or portal hypertension in the absence of other causes. In most cases, hepatic hydrothorax is seen in patients with ascites. However, ascites is not always found at diagnosis and is not clinically detected in 20% of patients with hepatic hydrothorax. Some patients have no symptoms and incidental findings on radiologic examination lead to the diagnosis of the condition. In the majority of cases, the patients present with symptoms such as dyspnea at rest, cough, nausea, and pleuritic chest pain. The diagnosis of hepatic hydrothorax is based on clinical manifestations, radiological features, and thoracocentesis to exclude other etiologies such as infection (parapneumonic effusion, tuberculosis), malignancy (lymphoma, adenocarcinoma) and chylothorax. The management strategy involves a stepwise approach of one or more of the following: Reducing ascitic fluid production, preventing fluid transfer to the pleural space, fluid drainage from the pleural cavity, pleurodesis (obliteration of the pleural cavity), and liver transplantation. The complications of hepatic hydrothorax are associated with significant morbidity and mortality. The complication that causes the highest morbidity and mortality is spontaneous bacterial empyema (also called spontaneous bacterial pleuritis).
Subject(s)
Hydrothorax , Liver Transplantation , Pleural Effusion , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Hydrothorax/therapy , Ascites/diagnosis , Ascites/etiology , Ascites/therapy , Pleural Effusion/diagnosis , Pleural Effusion/etiology , Pleural Effusion/therapy , Liver Cirrhosis/complications , Liver Cirrhosis/diagnosis , Liver Transplantation/adverse effectsABSTRACT
A 64-year-old female with chronic renal failure had been receiving continuous ambulatory peritoneal dialysis (CAPD). She developed acute hydrothorax in the right pleural cavity 1 year after the commencement of CAPD. Scintigraphy revealed a diagnosis of pleuroperitoneal communication, and we performed video-assisted thoracoscopic surgery. We infused a dialysis solution containing indocyanine green (ICG) through CAPD catheter. Near-infrared fluorescence thoracoscopy revealed a fistula that could not be identified by white light. We sutured the fistula covered with a polyglycolic acid sheet and fibrin glue. The CAPD was able to be resumed 8 days after surgery, and there was no recurrence of pleural effusion 10 months since surgery. Identification of the diaphragmatic fistula is important in the treatment of pleuroperitoneal communication. This technique using near-infrared fluorescence thoracoscopy with ICG was useful in identifying the fistula, and it emitted sufficient fluorescence even at low concentration ICG.
Subject(s)
Fistula , Hydrothorax , Peritoneal Dialysis, Continuous Ambulatory , Peritoneal Diseases , Pleural Diseases , Female , Humans , Middle Aged , Pleural Diseases/diagnostic imaging , Pleural Diseases/etiology , Pleural Diseases/surgery , Indocyanine Green , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Fluorescence , Peritoneal Diseases/surgery , Hydrothorax/diagnosis , Thoracic Surgery, Video-Assisted , Fistula/diagnostic imaging , Fistula/etiology , Fistula/surgeryABSTRACT
BACKGROUND: The Hepatic hydrothorax is a pleural effusion related to portal hypertension; its diagnosis and therapeutic management may be difficult. The aims of this article are which follows: To gather the practices of hepatogastroenterologists or pulmonologists practitioners regarding the diagnosis and management of the hepatic hydrothorax. METHODS: Practitioners from 13 French- speaking countries were invited to answer an online questionnaire on the hepatic hydrothorax diagnosis and its management. RESULTS: Five hundred twenty-eight practitioners (80% from France) responded to this survey. 75% were hepatogastroenterologists, 20% pulmonologists and the remaining 5% belonged to other specialities. The Hepatic hydrothorax can be located on the left lung for 64% of the responders (66% hepatogastroenterologists vs 57% pulmonologists; p = 0.25); The Hepatic hydrothorax can exist in the absence of clinical ascites for 91% of the responders (93% hepatogastroenterologists vs 88% pulmonologists; p = 0.27). An Ultrasound pleural scanning was systematically performed before a puncture for 43% of the responders (36% hepatogastroenterologists vs 70% pulmonologists; p < 0.001). A chest X-ray was performed before a puncture for 73% of the respondeurs (79% hepatogastroenterologists vs 54% pulmonologists; p < 0.001). In case of a spontaneous bacterial empyema, an albumin infusion was used by 73% hepatogastroenterologists and 20% pulmonologists (p < 0.001). A drain was used by 37% of the responders (37% hepatogastroenterologists vs 31% pulmonologists; p = 0.26).An Indwelling pleural catheter was used by 50% pulmonologists and 22% hepatogastroenterologists (p < 0.01). TIPS was recommended by 78% of the responders (85% hepatogastroenterologists vs 52% pulmonologists; p < 0.001) and a liver transplantation, by 76% of the responders (86% hepatogastroenterologists vs 44% pulmonologists; p < 0.001). CONCLUSIONS: The results of this large study provide important data on practices of French speaking hepatogastroenterologists and pulmonologists; it appears that recommendations are warranted.
Subject(s)
Gastroenterologists , Hydrothorax , Hypertension, Portal , Pleural Effusion , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Hydrothorax/therapy , Pulmonologists , Pleural Effusion/diagnosis , Pleural Effusion/etiology , Pleural Effusion/therapyABSTRACT
Hepatic hydrothorax refers to the presence of a pleural effusion (usually >500 mL) in a patient with cirrhosis who does not have other reasons to have a pleural effusion (e.g., cardiac, pulmonary, or pleural disease). Hepatic hydrothorax occurs in approximately 5-6% of patients with cirrhosis. It results from the ascitic fluid draining into the pleural cavity through the diaphragmatic defects. The presentation of patients with hepatic hydrothorax includes chest pain, hypoxemia, cough, shortness of breath and fatigue. The atypical feature, in this case, is the presence of hepatic hydrothorax in a patient with chronic liver disease without ascites. The management of hepatic hydrothorax is difficult. The initial treatment should be a low-salt diet plus diuretics. The best diuretic regimen is probably the combination of furosemide and spironolactone. However, about 25% of patients are refractory to this regimen, and additional therapy is indicated. This patient underwent thoracentesis, however, considering the re-accumulation of fluid, a pigtail catheter was placed which drained up to 8 liters of fluid.
Subject(s)
Hydrothorax , Pleural Effusion , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Hydrothorax/therapy , Ascites/diagnosis , Ascites/etiology , Ascites/therapy , Pleural Effusion/diagnosis , Pleural Effusion/etiology , Pleural Effusion/therapy , Liver Cirrhosis/complications , DrainageABSTRACT
A 72-year-old man was introduced continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure. Five months later, he was pointed out a massive right pleural effusion. Being diagnosed with pleuroperitoneal communication, he was referred to our department for surgery. Dialysis fluid and indocyanine green were injected through a peritoneal catheter for CAPD 30 minutes before surgery. A small fistula was detected by pressing the abdomen and using infrared thoracoscopy. The fistula was sutured and covered with polyglycolic acid sheet and fibrin glue. A day after surgery, CAPD was resumed. He was discharged on the post operative sixth day without any complications.
Subject(s)
Fistula , Hydrothorax , Kidney Failure, Chronic , Peritoneal Dialysis, Continuous Ambulatory , Peritoneal Diseases , Pleural Diseases , Aged , Humans , Male , Fibrin Tissue Adhesive , Fistula/surgery , Hydrothorax/diagnosis , Hydrothorax/etiology , Hydrothorax/surgery , Indocyanine Green , Kidney Failure, Chronic/therapy , Kidney Failure, Chronic/complications , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Peritoneal Diseases/etiology , Peritoneal Diseases/surgery , Pleural Diseases/etiology , Pleural Diseases/surgery , Pleural Diseases/diagnosis , Polyglycolic AcidABSTRACT
BACKGROUND: The clinical features and factors affecting the prognostic survival of hepatic hydrothorax (HH) are currently unknown. METHODS: We conducted a retrospective cohort study of 131 patients with HH using the Kaplan-Meier method and Cox proportional hazards regression analysis to assess factors influencing the prognosis of HH. RESULTS: A total of 131 patients were enrolled: the male to female ratio was 80:51 (1.59:1), and the mean age was 52.76 ± 11.88 years. Hepatitis B cirrhosis was the main cause of HH, and abdominal distention and dyspnea were the most common clinical signs. Ascites was present in varying amounts in all patients and was the most common decompensated complication, with pleural effusions mostly seen on the right side (107/131; 82%), followed by the left side (16/131; 12%) and bilateral effusions (8/131; 6%). For overall survival without transplantation, the estimated median survival time was 21 (95% confidence interval [CI]:18-25) months, and survival rates at 6 months, 1 year, and 2 years were 77.2%, 62.4%, and 29.7%, respectively. After controlling for covariates that were associated with liver-related mortality in the univariate analysis, males (hazard ratio [HR]: 1.721, 95% CI: 1.114-2.658, P = 0.005) and combined hepatic encephalopathy (HR: 2.016, 95% CI: 1.101-3.693, P = 0.001) were found to be associated with an increase in liver-related mortality. CONCLUSIONS: In this cohort of HH patients without liver transplantation, male sex and hepatic encephalopathy were associated with a higher risk of liver-related death.
Subject(s)
Hepatic Encephalopathy , Hydrothorax , Adult , Female , Hepatic Encephalopathy/complications , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Liver Cirrhosis , Male , Middle Aged , Prognosis , Retrospective StudiesABSTRACT
BACKGROUND: Spontaneous bacterial empyema (SBE) is an infection of a preexisting hepatic hydrothorax (HH). We aim to describe the experience in managing SBE in a liver transplant (LT) referral center and assessing the incidence and mortality rates of SBE after conducting a systematic review. METHODS: 992 patients with cirrhosis were retrospectively reviewed from 2015 to 2020. SBE was diagnosed by (i) positive microbiological culture and polymorphonuclear leukocyte count >250 cells/µL or (ii) negative microbiological culture, compatible clinical course, and polymorphonuclear count >500 cells/µL in pleural fluid. Furthermore, we conducted a comprehensive literature search of MEDLINE, EMBASE, and Google Scholar for studies evaluating SBE. RESULTS: Twelve patients (10.4%) had spontaneous bacterial empyema out of 115 patients with HH. Five patients underwent LT, 6 had died, and 1 did not get transplanted and was alive throughout the duration of follow-up. Ten studies were included in the systematic review. Pooled incidence in patients with HH was 19.03%. Only 20.69% of the patients received a LT. Pooled mortality rate was 46.45%, with only 3.45% of the patients dying post-transplant. CONCLUSION: SBE is a severe complication of cirrhosis and HH. LT may provide a survival benefit. Thus, patients should be considered for early transplant.
Subject(s)
Empyema , Hydrothorax , Empyema/diagnosis , Empyema/epidemiology , Empyema/etiology , Humans , Hydrothorax/complications , Hydrothorax/diagnosis , Liver Cirrhosis/complications , Liver Cirrhosis/diagnosis , Retrospective Studies , Tertiary Care CentersABSTRACT
BACKGROUND: Spontaneous bacterial empyema (SBEM) is a rare complication of hepatic hydrothorax characterized by hydrothorax infection in the absence of pneumonia. AIMS AND METHODS: We conducted this study to compare clinical outcomes in SBEM patients who underwent early thoracentesis (ET) (≤ 24 h from presentation) versus those who underwent delayed thoracentesis (DT). All patients diagnosed with SBEM at Mayo Clinic Rochester, Minnesota from January 1st 1999 to December 31st 2020 were reviewed. Demographics, pleural fluid studies, laboratory results and clinical outcomes were analyzed. RESULTS: A total of 54 SBEM patients (27 ET and 27 DT) were identified with 38 (70.4%) of patients presenting with right-sided effusions. Both groups had similar baseline characteristics. The rate of ICU admission was significantly higher in the DT group (15 (55.6%) vs. 7 (25.9%) patients, P = 0.027). Patients with DT had similar rate of AKI (11 (40.7%) vs. 6 (22.2%) patients, P = 0.074). In-hospital mortality (11 (40.7%) vs. 2 (7.4%) patients, P = 0.004), 3-month mortality (16 (59.3%) vs. 2 (7.4%) patients, P < 0.001) and 1-year mortality rate (21 (77.8%) vs. 6 (22.2%) patients, P < 0.001) were higher in the DT group. CONCLUSION: Patients with SBEM who underwent thoracentesis after 24 h from presentation (DT) had higher rates of mortality and ICU admission compared to patients who received early thoracentesis. Thoracentesis should be performed early in patients with suspected SBEM since it may improve survival.
Subject(s)
Empyema , Hydrothorax , Empyema/complications , Empyema/microbiology , Humans , Hydrothorax/complications , Hydrothorax/diagnosis , Liver Cirrhosis/complications , Thoracentesis/adverse effectsABSTRACT
Pleural effusions (PEs) are frequently encountered in routine clinical practice, affecting more than 3000 people per million population every year. Heart and liver failures are two of the most common causes of transudative PE. Because these effusions have nonmalignant etiologies, they are commonly referred to as benign effusions despite of the poor prognosis they foretell in their refractory stages. Like malignant effusions, symptom management is important and plays a significant role in palliation when these effusions become refractory to medical therapy.
Subject(s)
Heart Failure , Hydrothorax , Pleural Effusion, Malignant , Pleural Effusion , Heart Failure/diagnosis , Heart Failure/etiology , Heart Failure/therapy , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Hydrothorax/therapy , Liver , Pleural Effusion/diagnosis , Pleural Effusion/etiology , Pleural Effusion/therapy , Pleural Effusion, Malignant/diagnosis , Pleural Effusion, Malignant/etiology , Pleural Effusion, Malignant/therapyABSTRACT
To describe a rare case of unilateral massive hydrothorax after controlled ovarian stimulation for IVF and to analyze the diagnostic complexities in a patient lacking both risk factors and typical features of ovarian hyperstimulation syndrome (OHSS). We present a case of a 35-year-old woman suffering from primary infertility due to a severe male factor. Admitted to hospital for dyspnea, the patient initially underwent a thoracentesis. Later, due to the recurrence of massive hydrothorax, permanent pleural drainage was placed. Recognized as a severe manifestation of the OHSS, it was treated by pleural drainage, hydration, albumin perfusion, and management of the intercurrent pregnancy, up to improvement in clinical and hematological laboratory parameters and resolution of pleural effusion and respiratory symptoms. A total of 42 l of pleural fluid was drained during the 40 days of hospitalization. Since the pathogenesis of isolated acute hydrothorax in ovarian stimulation probably lies in the presence of anatomical defects of the diaphragm, this may justify that the relationship between this pathology and the OHSS risk factors may be less close. Massive pleural effusion may exceptionally be the only clinical presentation of OHSS. A high index of suspicion is necessary to make the correct diagnosis and to promptly administer treatment.
Subject(s)
Fertilization in Vitro/adverse effects , Hydrothorax/diagnosis , Ovarian Hyperstimulation Syndrome/diagnosis , Pleural Effusion/diagnosis , Adult , Female , Humans , Hydrothorax/etiology , Ovarian Hyperstimulation Syndrome/etiology , Pleural Effusion/etiologySubject(s)
Evidence-Based Medicine/methods , Hydrothorax/therapy , Liver Cirrhosis/therapy , Patient Care Team , Combined Modality Therapy/methods , Gastroenterology/methods , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Hydrothorax/mortality , Liver Cirrhosis/complications , Liver Cirrhosis/mortality , Pulmonary Medicine/methods , Radiology, Interventional/methods , Specialties, Surgical/methods , Survival Analysis , Treatment OutcomeABSTRACT
Hepatic hydrothorax is a transudative pleural effusion that complicates advanced liver cirrhosis. Patients refractory to medical treatment plus salt restriction and diuretics are considered to have refractory hepatic hydrothorax and may require transjugular intrahepatic portosystemic shunt (TIPS) or liver transplant. Successful antiviral therapy reduces the incidence of some complications of cirrhosis secondary to HCV infection. We report a case of hepatic hydrothorax in a 55-year-old female patient with HCV cirrhosis, which exhibited a spontaneous decrease in pleural effusion after direct antiviral agent (DAA) therapy. In cases of HCV cirrhosis, DAAs are worth administering before treatment by TIPS or liver transplantation.
Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Hydrothorax/diagnosis , Drug Administration Schedule , Female , Hepatitis C, Chronic/complications , Humans , Hydrothorax/complications , Liver Cirrhosis/complications , Middle Aged , Sustained Virologic Response , Tomography, X-Ray ComputedABSTRACT
Cirrhotic cardiomyopathy (CCM) is a chronic cardiac dysfunction in patients with cirrhosis and is characterized by altered diastolic relaxation, blunted contractile response to stress, and electrophysiological abnormalities;however, causes of CCM are unknown. Moreover, reduced cardiac afterload due to cirrhosis-related vasodilatation often masks cardiac insufficiency, whereas rapid hemodynamic overload reveals the presence of cirrhotic cardiomyopathy. Herein, we present the case of previously unrecognized cirrhotic cardiomyopathy that became overt with the development of severe acute cardiac failure. The rapidly worsening hepatic hydrothorax increased cardiac preload and intrathoracic pressure, which impaired cardiac filling. Furthermore, cardiac contractile function might have been worsened by hypoxia due to passive atelectasis and concomitant anemia.
Subject(s)
Cardiomyopathies/diagnosis , Heart Failure/diagnosis , Hydrothorax/diagnosis , Liver Cirrhosis, Alcoholic/diagnosis , Liver Cirrhosis , Cardiomyopathies/complications , Heart Failure/complications , Humans , Hydrothorax/complications , Liver Cirrhosis, Alcoholic/complicationsABSTRACT
Patients with end-stage liver disease (ESLD) who require intensive care unit admission have high rates of mortality. This article reviews the pathophysiology and emergency department assessment and management of the most frequent conditions and complications encountered in critically ill ESLD patients including hepatic encephalopathy, gastrointestinal bleeding, sepsis and bacterial peritonitis, hepatorenal syndrome, severe coagulopathy, and hepatic hydrothorax.
Subject(s)
Critical Illness , End Stage Liver Disease/complications , End Stage Liver Disease/therapy , Airway Management/methods , Disseminated Intravascular Coagulation/diagnosis , Disseminated Intravascular Coagulation/etiology , Disseminated Intravascular Coagulation/therapy , Emergency Medicine , Esophageal and Gastric Varices/complications , Esophageal and Gastric Varices/therapy , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/therapy , Hepatic Encephalopathy/diagnosis , Hepatic Encephalopathy/etiology , Hepatic Encephalopathy/therapy , Hepatorenal Syndrome/diagnosis , Hepatorenal Syndrome/etiology , Hepatorenal Syndrome/therapy , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Hydrothorax/therapy , Hyperammonemia/etiology , Hyperammonemia/therapy , Intensive Care Units , Liver Transplantation , Peritonitis/diagnosis , Peritonitis/etiology , Peritonitis/therapy , Risk Assessment , Severity of Illness IndexSubject(s)
Autopsy/history , Edema/diagnosis , Liver Cirrhosis/diagnosis , Sepsis/diagnosis , Aged , Ascites , Bacterial Infections/complications , Bacterial Infections/diagnosis , Edema/complications , Fever , Gangrene , History, 17th Century , History, 18th Century , Humans , Hydrothorax/complications , Hydrothorax/diagnosis , Jurisprudence , Liver Cirrhosis/complications , Male , Pancreatitis, Chronic/complications , Pancreatitis, Chronic/diagnosis , Sepsis/complications , Weight LossABSTRACT
Hepatic hydrothorax is a challenging complication of cirrhosis related to portal hypertension with an incidence of 5-11% and occurs most commonly in patients with decompensated disease. Diagnosis is made through thoracentesis after excluding other causes of transudative effusions. It presents with dyspnea on exertion and it is most commonly right sided. Pathophysiology is mainly related to the direct passage of fluid from the peritoneal cavity through diaphragmatic defects. In this updated literature review, we summarize the diagnosis, clinical presentation, epidemiology and pathophysiology of hepatic hydrothorax, then we discuss a common complication of hepatic hydrothorax, spontaneous bacterial pleuritis, and how to diagnose and treat this condition. Finally, we elaborate all treatment options including chest tube drainage, pleurodesis, surgical intervention, Transjugular Intrahepatic Portosystemic Shunt and the most recent evidence on indwelling pleural catheters, discussing the available data and concluding with management recommendations.
Subject(s)
Hydrothorax/therapy , Liver Cirrhosis/therapy , Humans , Hydrothorax/diagnosis , Hydrothorax/epidemiology , Hydrothorax/physiopathology , Liver Cirrhosis/diagnosis , Liver Cirrhosis/epidemiology , Liver Cirrhosis/physiopathology , Predictive Value of Tests , Risk Factors , Thoracentesis , Treatment OutcomeABSTRACT
BACKGROUND: Pleuroperitoneal communication is a serious complication in patients receiving continuous ambulatory peritoneal dialysis. However, few single-institutional reports discuss the details of pleuroperitoneal communication in continuous ambulatory peritoneal dialysis patients regarding the intraoperative findings, postoperative course, and outcomes. METHODS: We retrospectively reviewed the records of consecutive pleuroperitoneal communication patients who were treated surgically from September 2008 to March 2016. RESULTS: All four patients had right-sided hydrothorax. The time from introduction of continuous ambulatory peritoneal dialysis to the diagnosis of hydrothorax ranged from 1 to 12 months (average: 5.5 months). Case 1 and case 4 had bleblike lesions near the center of the diaphragm; case 2 had a small hole located near the cardiophrenic angle, and case 3 had thinning of the diaphragm near the cardiophrenic angle. All lesions except for case 3 were directly closed with absorbable suture and reinforced by fibrin glue and a polyglycolic acid sheet. In case 3, the thinned diaphragm was reinforced using fibrin glue, a sealing sheet, and pericardial fat pad tissue. Continuous ambulatory peritoneal dialysis was reinitiated an average period of 11 days (range: 4-15 days) postoperatively. During postoperative follow-up, there was no recurrence of hydrothorax. Continuous ambulatory peritoneal dialysis was continued for an average of 16.7 months (range: 3-34 months) after surgical treatment. CONCLUSIONS: Surgical treatment for pleuroperitoneal communication is a safe and acceptable procedure and could greatly benefit continuous ambulatory peritoneal dialysis patients.
Subject(s)
Hydrothorax/surgery , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Peritoneal Diseases/surgery , Pleural Diseases/surgery , Adolescent , Aged , Humans , Hydrothorax/diagnosis , Hydrothorax/etiology , Male , Middle Aged , Peritoneal Diseases/diagnosis , Peritoneal Diseases/etiology , Pleural Diseases/diagnosis , Pleural Diseases/etiology , Retrospective Studies , Treatment OutcomeABSTRACT
BACKGROUND: The outcome of indwelling pleural catheter (IPC) use in hepatic hydrothorax (HH) is unclear. This study aimed to review the safety and feasibility of the IPC in patients with refractory HH. METHODS: A retrospective multicenter study of patients with HH from January 2010 to December 2016 was performed. Inclusion criteria were refractory HH treated with an IPC and an underlying diagnosis of cirrhosis. Records were reviewed for patient demographics, operative reports, and laboratory values. The Kaplan-Meier method was used to estimate catheter time to removal. The Cox proportional hazard model was used to evaluate for independent predictors of pleurodesis and death. RESULTS: Seventy-nine patients were identified from eight institutions. Indication for IPC placement was palliation in 58 patients (73%) and bridge to transplant in 21 patients (27%). The median in situ dwell time of all catheters was 156 days (range, 16-1,978 days). Eight patients (10%) were found to have pleural space infection, five of whom also had catheter-site cellulitis. Two patients (2.5%) died secondary to catheter-related sepsis. Catheter removal secondary to spontaneous pleurodesis was achieved in 22 patients (28%). Median time from catheter insertion to pleurodesis was 55 days (range, 10-370 days). Older age was an independent predictor of mortality on multivariate analysis (hazard ratio, 1.05; P = .01). CONCLUSIONS: We present, to our knowledge, the first multicenter study examining outcomes related to IPC use in HH. Ten percent infection risk and 2.5% mortality were identified. IPC placement may be a reasonable clinical option for patients with refractory HH, but it is associated with significant adverse events in this morbid population.